tradit
vaccin
compos
either
whole
pathogen
part
vaccin
howev
alway
effect
even
harm
addit
agent
known
adjuv
necessari
increas
vaccin
safeti
efficaci
review
summar
potenti
biodegrad
materi
includ
synthet
natur
polym
vaccin
deliveri
materi
highli
biocompat
minim
toxic
biomaterialbas
vaccin
deliv
antigen
adjuv
shown
improv
immun
respons
compar
formul
consist
antigen
alon
therefor
materi
appli
modern
vaccin
develop
vaccin
significantli
improv
human
health
save
countless
live
variou
diseas
tradit
vaccin
compos
either
whole
pathogen
part
induc
robust
immun
respons
howev
effect
emerg
pathogen
mycobacterium
tuberculosi
human
immunodefici
viru
hiv
hepat
c
viru
instead
caus
advers
effect
safeti
concern
forc
vaccin
maker
shift
focu
subunit
vaccin
compos
nucleic
acid
recombin
protein
short
peptid
sequenc
favor
safeti
efficaci
may
thu
requir
addit
immun
stimul
agent
known
adjuv
essenti
compon
modern
vaccin
made
inorgan
polymer
materi
macromolecular
complex
design
enhanc
vaccin
potenc
perdur
immun
respons
numer
compound
includ
saponin
lecithin
miner
oil
agar
investig
abil
enhanc
effect
antigen
ag
although
function
adjuv
preclin
anim
model
identifi
toxic
therefor
unsuit
use
human
left
aluminum
compound
use
either
alon
combin
compound
major
adjuv
human
vaccin
howev
becom
increasingli
clear
ineffect
ebola
influenza
tuberculosi
hiv
infect
malaria
requir
complex
immun
respons
includ
activ
cellmedi
immun
recent
outbreak
ebola
middl
east
respiratori
syndrom
alarm
medic
commun
demonstr
urgent
need
safe
effect
vaccin
combat
infecti
diseas
end
novel
vaccin
deliveri
method
adjuv
investig
latter
requir
develop
complementari
strategi
enhanc
immun
respons
toward
given
ag
howev
critic
challeng
develop
adjuv
increas
potenc
minim
toxic
compound
reach
clinic
trial
stage
biolog
licens
applic
vaccin
requir
evid
strong
safetyefficaci
data
multicent
trial
puriti
potenc
consist
manufactur
lot
also
import
stringent
regul
pose
addit
challeng
develop
new
adjuv
recent
polymer
biomaterialbas
vaccin
deliveri
system
adjuv
emerg
altern
classic
alumbas
adjuv
summari
recent
advanc
applic
biomateri
vaccin
adjuv
ag
carrier
present
fig
studi
mechan
trigger
polymer
biomateri
reli
activ
pathogen
pattern
recognit
receptor
prr
local
surfac
cytoplasm
immun
cell
particularli
dendrit
cell
dc
macrophag
howev
recent
studi
show
cell
type
like
mast
cell
mc
also
import
physiolog
role
modul
appropri
immun
respons
one
promis
deliveri
strategi
control
releas
vaccin
biodegrad
polymer
matrix
two
major
function
biomaterialbas
adjuv
ag
deliveri
immun
stimul
biomateri
biocompat
natur
synthet
substanc
engin
interact
biolog
system
favor
physiochem
properti
includ
high
surfac
area
biofunction
multival
conjug
eas
surfac
modif
specif
cell
target
flexibl
size
micro
nano
scale
high
ag
load
capac
vivo
stabil
respons
stimuli
environ
polymer
biomateri
enhanc
immun
respons
follow
way
increas
stabil
ag
prevent
degrad
encapsul
adsorpt
incorpor
multipl
adjuv
ag
therebi
enhanc
immunogen
weak
ag
effect
taken
process
agpres
cell
apc
enhanc
crosspresent
major
histocompat
complex
class
mhc
mediat
cytotox
cell
immun
respons
flexibl
term
surfac
function
enabl
activ
target
apc
activ
endosom
tlr
surfac
prr
elicit
robust
immun
respons
fig
collect
novel
vaccin
adjuv
deliveri
system
mani
advantag
classic
vaccin
includ
improv
safeti
higher
immunogen
stimul
multipl
immun
respons
pathway
especi
cellmedi
immun
ie
involv
helper
cell
th
greater
flexibl
rout
administr
system
nasal
subcutan
transderm
make
broadli
applic
eg
cancer
autoimmun
diseas
tuberculosi
tb
numer
natur
synthet
biodegrad
polym
investig
vaccin
develop
develop
controlledreleas
vaccin
hamper
instabl
ag
encapsul
process
low
encapsul
adsorpt
effici
colloid
instabl
hinder
clinic
translat
sinc
modern
vaccin
formul
tailor
current
clinic
requir
care
select
ag
adjuv
extrem
import
biomateri
complex
immunolog
mechan
well
understood
review
summar
potenti
variou
biodegrad
materi
adjuv
discuss
ration
design
novel
ag
carrier
adjuv
use
repres
natur
synthet
biodegrad
polym
fig
exampl
also
critic
evalu
variou
factor
contribut
immun
stimul
highlight
recent
applic
biodegrad
materialbas
adjuv
vaccin
biodegrad
polym
use
vaccin
adjuv
stimul
immun
system
carrier
vaccin
deliveri
numer
form
adjuv
vaccin
carrier
develop
thu
far
synthet
natur
biodegrad
polym
particl
microcapsul
microspher
nanospher
use
vaccin
carrier
adjuv
function
encapsul
adsorpt
ag
encapsul
within
particl
increas
stabil
ag
therebi
deliv
vaccin
apc
effici
stimul
immun
respons
particl
use
immunostimulatori
adjuv
via
surfac
adsorpt
coat
ag
membran
microand
nanoparticl
order
enhanc
immun
respons
nanometers
polymer
nanogel
hydrogel
nanoparticl
swollen
network
amphiphil
hydrophil
polyion
polym
nanogel
promis
multifunct
polymer
nanoparticl
potenti
use
deliveri
system
uniqu
properti
includ
multival
conjug
high
water
content
biocompat
nanogel
design
use
differ
approach
physic
selfassembl
interact
polym
polymer
monom
homogen
phase
microor
nanoscal
heterogen
environ
crosslink
preform
polym
templateassist
nanofabr
sever
synthet
natur
biodegrad
polym
use
develop
nanogel
microneedl
micronscal
structur
painlessli
pierc
skin
administ
vaccin
ag
encapsul
within
polym
microneedl
insert
skin
biocompat
polym
dissolv
within
minut
releas
vaccin
polyvinylpyrrolidon
pvp
use
make
microneedl
chemic
backbon
structur
vinyl
pyrrolidon
monom
ring
increas
intramolecular
rigid
provid
mechan
strength
polym
import
microneedl
insert
skin
pvp
also
high
water
solubl
facilit
rapid
dissolut
process
electrospin
provid
uniqu
possibl
produc
fiber
vari
poros
thu
high
surfac
area
high
surfac
areavolum
ratio
fiber
combin
potenti
biocompat
biodegrad
natur
offer
tremend
promis
biomed
applic
target
vaccin
deliveri
one
studi
vaccin
involv
deliveri
shigella
antigen
nonwoven
chitosan
nanofibr
membran
membran
produc
process
electrospin
contain
ntermin
region
ipad
shigella
subunit
antigen
aqueou
chitosan
untreat
hydrolyz
acoh
solut
dilut
recombin
antigen
use
encapsul
process
volum
ratio
creat
final
recombin
antigen
concentr
mgml
solut
use
electrospin
layerbylay
lbl
assembl
nanoengin
hydrogel
capsul
exampl
potent
technolog
protect
deliveri
labil
vaccin
candid
apc
encapsul
hydrogel
capsul
protect
vaccin
degrad
ensur
deliveri
high
payload
antigen
apc
particul
natur
capsul
make
subject
phagocytosi
profession
apc
macropinocytosi
dc
target
deliveri
vaccin
key
cell
initi
immun
respons
chitosan
hydrogel
sustainedreleas
vaccin
deliveri
system
primarili
consist
natur
occur
polym
chitosan
chitosan
solut
alter
addit
polyol
salt
thermosensit
hydrogel
form
bodi
temperatur
provid
easili
inject
subcutan
depot
system
incorpor
adjuv
solut
room
temperatur
numer
synthet
biopolym
includ
polyest
polylactid
polyglycolid
poli
lacticcoglycol
acid
plga
polycaprolacton
pcl
polyphosphazen
polyanhydrid
investig
potenti
vaccin
deliveri
briefli
discuss
factor
influenc
potenc
adjuv
biodegrad
synthet
polym
commonli
use
biomed
applic
includ
aliphat
polyest
poli
lactic
acid
pla
plga
pcl
well
copolym
divers
famili
synthet
biodegrad
thermoplast
polym
investig
potenti
adjuv
vaccin
carrier
synthet
polyest
excel
biocompat
safeti
profil
approv
us
food
drug
administr
usfda
european
medicin
agenc
biomed
applic
poli
glycol
acid
pga
poli
lactic
acid
pla
pga
highli
crystallin
materi
suscept
hydrolysi
due
ester
bond
present
polym
backbon
pga
rapidli
degrad
lack
mechan
strength
produc
acid
environ
hydrolysi
pga
glycolid
result
activ
classic
complement
pathway
lead
strong
undesir
inflammatori
respons
pla
anoth
import
synthet
biopolym
exist
differ
isom
poli
llactic
acid
poli
dlactic
acid
studi
context
vaccin
develop
addit
methyl
group
pla
structur
increas
hydrophob
stabil
hydrolysi
compar
pga
pla
use
prepar
microcapsul
microspher
nanospher
usual
design
achiev
either
control
puls
releas
prolong
period
effect
singl
vaccin
deliveri
puls
releas
ag
biopolym
matrix
essenti
earlier
studi
report
enhanc
memori
antibodi
respons
upon
immun
singl
dose
tetanu
toxin
tt
diphtheria
toxin
dt
load
pla
particl
mani
studi
sinc
highlight
advantag
plapolyethylen
glycol
peg
nanocarri
exampl
verma
et
al
report
plapegencapsul
peptid
deriv
major
outer
membran
protein
momp
chlamydia
nanovaccin
elicit
strong
cellmedi
immun
effector
respons
mix
respons
mucos
iga
respons
protect
mice
chlamydi
genit
tract
challeng
major
advantag
anion
pla
biopolym
possibl
encapsul
adsorpt
one
numer
antigen
togeth
adjuv
molecul
like
receptor
ligand
improv
immunogen
potenti
ag
surfac
adsorpt
hiv
type
ag
surfactantfre
anion
nanoparticl
np
shown
induc
cell
immun
respons
experiment
anim
immun
subcutan
similarli
coadsorpt
glycoprotein
gp
ag
planp
surfac
show
strong
immunogen
coencapsul
tolllik
receptor
tlr
ovalbumin
ova
ag
pla
microparticl
elicit
enhanc
immun
respons
recent
studi
compar
adjuv
potenti
pla
microparticl
alum
influenza
split
vaccin
reveal
pla
microparticl
stimul
humor
cellular
immun
respons
wherea
alum
alon
induc
former
find
indic
pla
biopolym
promis
biomateri
singleshot
vaccin
reduc
necess
booster
dosag
therebi
reduc
cost
likelihood
advers
reaction
plga
copolym
synthes
random
polymer
pla
pga
biodegrad
plga
yield
biocompat
lactic
glycol
acid
ultim
remov
bodi
citric
acid
cycl
composit
plga
determin
ag
adjuv
encapsul
releas
profil
plga
polym
differ
stoichiometr
ratio
lactic
glycol
acid
differ
molecular
weight
exhibit
differ
ag
stabil
releas
kinet
instanc
plga
monom
ratio
degrad
time
month
respect
thu
releas
kinet
predict
differ
ag
adjuv
allow
longterm
immun
respons
obtain
singl
vaccin
without
associ
toxic
plgabas
ag
carrier
prepar
microspher
microcapsul
nanospher
facilit
control
deliveri
ag
payload
poliomyel
potenti
fatal
vaccineprevent
infecti
diseas
howev
ml
liquid
inactiv
polio
vaccin
ipv
formul
administ
two
three
inject
effect
infeas
countri
patient
may
easi
regular
access
healthcar
interestingli
tzeng
et
al
develop
inject
microparticl
formul
inactiv
polio
vaccin
ipv
releas
multipl
puls
stabl
antigen
time
singl
vaccin
technolog
current
particular
interest
success
erad
requir
enorm
coverag
rate
ensur
diseas
carri
transmit
unvaccin
individu
plga
numer
advantag
dendrit
cell
dc
target
high
stabil
eas
process
protract
releas
howev
also
limit
product
acid
microenviron
reduc
ag
stabil
higher
hydrophob
decreas
encapsul
effici
initi
burst
releas
therebi
alter
ag
releas
kinet
nevertheless
effect
easili
overcom
inclus
magnesium
hydroxid
calcium
carbon
compar
alum
adjuv
plga
biopolym
inert
carrier
unless
specif
composit
carri
immunostimul
adjuv
properti
plga
particl
complex
gener
uptak
ag
adjuv
apc
facilit
deliveri
payload
particul
rather
solubl
form
cellular
uptak
nanoand
micros
plga
particl
well
document
plga
particl
protect
ag
prematur
proteolyt
degrad
function
vaccin
deliveri
varieti
adjuv
bacteri
hepat
b
viru
hbv
surfac
ag
hbsag
hipb
viral
influenza
parasit
malaria
ag
encapsul
adsorb
onto
plga
nanomicroparticl
howev
clinic
develop
plganp
present
sever
challeng
includ
synthet
hydrophob
surfac
low
transfect
effici
dna
vaccin
short
circul
halflif
nonspecif
tissu
distribut
other
investig
variou
surfac
engin
strategi
overcom
problem
plga
biopolym
consider
flexibl
term
surfac
modif
function
target
plga
particl
function
human
target
antibodi
encapsul
ag
effici
taken
dc
elicit
potent
agdepend
cell
respons
even
low
concentr
similarli
surfac
modif
anion
plga
mucoadhes
polym
n
propyl
n
n
ntrimethylammonium
chitosan
ntrimethyl
chitosan
glycolchitosan
enhanc
mucoadhes
lead
greater
mucos
immun
respons
fig
surfac
modif
strategi
appli
develop
oral
mucos
vaccin
hiv
ag
oral
vaccin
plga
load
hiv
peptid
ag
togeth
poli
c
cpg
design
releas
larg
intestin
surfac
coat
phrespons
methacrylatebas
eudragit
polym
potent
induc
colorect
immun
protect
mice
rectal
vagin
viral
challeng
physicochem
properti
plgabas
particul
vaccin
ration
optim
allow
target
deliveri
ag
modul
local
immun
respons
microns
plga
particl
effici
stimul
humor
respons
wherea
nanos
particl
nm
promot
cellular
respons
thu
surfac
modif
target
function
enhanc
immunogen
properti
plga
biopolymerbas
nanomicroparticl
allow
rapid
clinic
translat
addit
plga
nanoparticl
use
major
core
materi
develop
biomimet
nanovaccin
platform
new
gener
biomimet
nano
vaccin
bmnv
prepar
use
cell
membran
coat
technolog
whole
cancer
cell
membran
ccm
ccmderiv
vesicl
use
cell
mimick
sourc
bmnv
platform
mimin
key
featur
surfac
molecular
organ
physicochem
properti
size
shape
biolog
entiti
emerg
new
concept
cancer
vaccin
develop
integr
synthet
plga
nanoparticl
wrap
cancer
cell
deriv
membran
ccmc
hold
tremend
potenti
cancer
immunotherapi
ccmc
offer
full
array
tumorassoci
antigen
taa
immun
cell
therebi
stimul
robust
tumorspecif
immun
respons
previous
carri
extens
research
prepar
cell
membran
coat
plga
nanoparticl
demonstr
potenti
biomed
applic
recent
studi
jin
et
al
demonstr
potenti
applic
human
primari
glioblastoma
ccm
coat
plganp
cancer
immunotherapi
subcutan
inject
np
trigger
tumorspecif
immun
respons
induc
lymphocyt
lymph
node
spleen
balbc
mous
model
pcl
semicrystallin
polyest
melt
temperatur
c
c
glass
transit
temperatur
c
investig
vaccin
carrier
adjuv
contrast
plga
pcl
degrad
slowli
gener
acid
environ
pcl
also
excel
biocompat
adjuv
potenti
pclbase
microparticl
schistosoma
mansoni
ag
oral
vaccin
deliveri
test
anoth
studi
compar
immunogen
nasal
oral
administ
recombin
mansoni
ag
encapsul
plga
pcl
microparticl
research
test
hot
salin
extract
brucella
ovi
encapsul
pcl
microparticl
vaccin
brucellosi
infect
mice
found
pclhardystonit
extract
b
ovi
vaccin
enhanc
agspecif
immunogen
oral
administr
particl
activ
interferon
ifn
g
interleukin
il
andto
lesser
indic
mix
cellular
immun
respons
studi
compar
pcl
plga
plgapcl
blend
polym
np
load
dt
ag
mucos
vaccin
deliveri
pcl
np
induc
potent
dtspecif
igg
antibodi
respons
plga
posit
correl
polym
hydrophob
intranas
administr
streptococcu
equi
ag
encapsul
pcl
np
gener
strong
mucos
immun
respons
secret
iga
mice
similarli
hbsagload
pcl
microspher
administ
intramuscularli
evok
greater
cellular
ifng
humor
igg
respons
balbc
mice
alumadjuv
vaccin
chitosanbas
surfac
modif
pcl
np
load
hemagglutinin
protein
gener
strong
cellular
system
mucos
immun
respons
upon
nasal
administr
recent
studi
investig
longterm
ag
releas
potenti
pcl
np
encapsul
tt
ag
compar
effect
pcl
np
size
small
nm
larg
nm
immunolog
respons
show
particl
nm
induc
macrophag
polar
polar
autolog
cell
cell
respons
wherea
larger
nm
particl
fail
induc
polar
pcl
reduc
aluminum
adjuv
system
tt
model
ag
induc
higher
level
ifng
convent
aluminumadjuv
formul
polyphosphazen
synthet
biodegrad
macromolecular
polym
phosphor
nitrogen
linearli
attach
altern
singl
doubl
bond
two
phosphor
side
group
open
conjug
via
esterif
etherif
amidif
mani
studi
demonstr
immunolog
adjuv
properti
polyphosphazen
polyphosphazenebas
polyelectrolyt
use
prepar
nanomicroag
carrier
ag
deliveri
poli
di
sodium
carboxlatophenoxi
phosphazen
pcpp
salt
potenti
mucos
adjuv
combin
variou
ag
pertussi
toxin
pneumococc
surfac
protein
formalininactiv
influenza
viru
trival
influenza
viru
hbsag
lai
incorpor
addit
polyphosphazen
immun
modul
show
superior
immunogen
multicarri
effici
pcpp
microparticl
demonstr
use
differ
ag
adjuv
fig
instanc
immunogen
respiratori
syncyti
viru
rsv
f
protein
ag
cpg
oligodeoxynucleotid
odn
immunomodulatori
innat
defens
regul
peptid
adjuv
encapsul
polyphosphazen
microparticl
stimul
strong
immun
respons
confer
complet
protect
rsvchalleng
anim
sever
studi
investig
mechan
action
polyphosphazen
suggest
poli
di
sodium
carboxylatoethylphenoxi
phosphazen
pcep
activ
inflammasom
caspasedepend
process
result
secret
furthermor
pcep
directli
activ
b
cell
produc
igm
increas
product
agspecif
ifng
cell
find
demonstr
polyphosphazenebas
synthet
biopolym
immunolog
potenti
adjuv
modern
vaccin
polyanhydrid
surfac
erod
biopolym
evalu
possibl
adjuv
ag
deliveri
metabolit
polyanhydrid
carboxyl
acid
biocompat
nonmutagen
approv
usfda
sinc
first
report
polyanhydridebas
carrier
capac
polyanhydrid
immun
stimul
ag
spare
singledos
vaccin
prolong
ag
exposur
immunolog
activ
explor
degrad
kinet
polyanhydrid
control
mix
rapidli
degrad
aliphat
polyanhydrid
slowli
degrad
aromat
counterpart
obtain
polym
encapsul
ag
stabl
manner
contrast
bulk
eros
plga
polym
polyanhydrid
degrad
surfac
eros
ensur
maxim
ag
releas
polyanhydrid
numer
advantag
synthet
polym
high
immunogen
capac
ag
stabil
sebac
acid
pcarboxyphenoxi
hexan
pcarboxyphenoxi
hydrophob
moieti
polyanhydrid
investig
adjuv
properti
divers
ag
biofunction
polyanhydrid
particl
result
enhanc
immun
respons
bioadhes
polym
mannos
flagellin
modifi
polyanhydrid
np
ova
ag
elicit
robust
system
mucos
immun
respons
anim
model
oral
immun
similar
studi
function
polyanhydrid
np
pathogenmimick
carbohydr
structur
galactos
dimannos
target
ctype
lectin
receptor
express
alveolar
macrophag
increas
particl
uptak
product
proinflammatori
cytokin
tumor
necrosi
factor
tnf
also
found
intern
nanoparticl
enhanc
express
activ
cell
fig
interestingli
agonistcpg
odnfunction
polyanhydrid
ova
ag
antitumor
effect
enhanc
cell
agspecif
igg
antibodi
respons
mice
thu
polyanhydrid
potenti
vaccin
adjuv
modul
immun
respons
induc
longterm
immun
singl
administr
deliv
ag
safe
continu
manner
via
multipl
rout
administr
natur
biopolym
attract
attent
control
deliveri
system
peptid
protein
dna
ag
addit
chitosan
protein
assembl
natur
occur
biopolym
dextran
mannan
propos
differ
vaccin
applic
interestingli
biopolym
present
cell
wall
variou
pathogen
includ
bacteria
yeast
thu
inher
target
apc
potenti
immun
respons
associ
ag
glucan
shown
enhanc
humor
cellular
immun
exert
adjuv
effect
bind
specif
carbohydr
receptor
lectin
mannan
receptor
express
monocyt
apc
result
activ
nuclear
factor
nf
kb
matur
monocyt
product
proinflammatori
cytokin
addit
natur
biopolym
biocompat
minim
toxic
make
ideal
candid
modern
vaccin
develop
natur
biopolymerbas
nanovaccin
prepar
simpl
method
solvent
displac
complex
ionic
gelat
reduc
use
organ
solvent
therebi
improv
stabil
biomolecul
biopolym
select
adjuv
vaccin
develop
high
puriti
safe
human
use
major
natur
biopolym
demonstr
adjuv
properti
applic
modern
vaccin
develop
describ
follow
section
advanc
biolog
microbiolog
technolog
increas
understand
pathogen
led
develop
newer
safer
subunit
ag
nevertheless
ag
less
effect
induc
protect
immun
respons
therefor
requir
parallel
develop
adjuv
immunomodulatori
molecul
particl
deliveri
system
polysaccharidebas
nanosystem
potenti
use
develop
vaccin
formul
fig
chitosan
natur
linear
poli
amino
saccharid
compos
glucana
copolym
glucosamin
nacetyl
glucosamin
obtain
alkalin
deacetyl
chitinthat
show
promis
immunolog
adjuv
chitosan
special
interest
mucos
vaccin
deliveri
owe
bioadhes
biocompat
low
toxic
mucoadhes
natur
chitosan
attribut
electrostat
interact
posit
charg
chitosan
neg
charg
sialic
acid
residu
mucos
surfac
chitosan
induc
redistribut
cytoskelet
factin
tight
junction
protein
zona
thu
promot
paracellular
permeabl
hydrophil
macromolecul
mucoadhes
properti
chitosan
prolong
resid
time
formul
mucosa
associ
lymphoid
tissu
malt
chitosan
deriv
formul
solut
gel
powder
microparticlesnp
deliv
ag
via
variou
rout
administr
chitosan
shown
activ
rat
macrophag
vitro
exert
local
system
effect
activ
cytokin
tnf
well
transform
growth
chitosan
increasingli
use
nanovaccin
develop
chitosanbas
nanovaccinedna
np
taken
cell
malt
chitosan
dna
nanospher
stimul
cytokin
cytotox
lymphocyt
ctl
respons
coadminist
ag
adjuv
inactiv
influenza
vaccin
administ
intramuscularli
mice
chitosan
increas
antibodi
titer
confer
protect
homolog
well
drift
variant
influenza
viru
furthermor
agspecif
humor
cellmedi
immun
respons
chitosan
deliv
subcutan
along
ag
higher
respons
nonadjuv
alumadjuv
group
anoth
studi
plachitosan
microparticl
encapsul
hbsag
stimul
serumspecif
igg
greater
extent
pla
hbsag
microparticl
free
hbsag
greater
adjuv
potenc
chitosan
rel
alum
inactiv
influenza
viru
vaccin
also
demonstr
mice
major
challeng
clinic
translat
chitosanbas
mucos
vaccin
uncontrol
precipit
physiolog
ph
howev
studi
conduct
human
subject
crm
formul
chitosan
show
promis
result
protect
mucos
vaccin
diphtheria
human
chitosanbas
nasal
deliveri
system
inactiv
subunit
influenza
vaccin
also
test
human
anoth
studi
show
chitosanadjuv
ag
higher
immunogen
alumadjuv
vaccin
healthi
human
volunt
swedish
compani
viscogel
ab
recent
develop
chitosanbas
adjuv
viscogel
found
safe
effect
preclin
studi
clinic
trial
chitosan
coadminist
acthib
vaccin
healthi
volunt
show
good
safeti
profil
effect
acthib
vaccin
alon
mannan
natur
biopolym
mannos
select
bind
mannanbind
lectin
mbl
ctype
lectin
mannos
receptor
famili
involv
phagocytosi
complement
activ
supplementari
opsonizationbas
immun
respons
mbl
interact
correl
dc
traffick
induct
humor
cellular
respons
mannan
deriv
reduc
oxid
form
dual
activ
toward
apcsnam
induc
phenotyp
variat
function
matur
dc
cell
deriv
also
induc
upregul
inflammatori
cytokin
well
cytokin
oxid
form
mannan
stimul
ctl
respons
high
ifng
secret
releas
predomin
antibodi
respons
wherea
reduc
form
stimul
respons
product
predomin
antibodi
respons
ifng
intranas
administr
oxid
mannan
recombin
protein
ag
induc
potent
immunolog
respons
cholera
toxin
product
siga
variou
mucos
secret
agspecif
serum
alo
polymannos
combin
coxsackieviru
murin
model
increas
agspecif
antibodi
product
capsid
protein
epitop
nonenvelop
picornaviru
compar
control
adjuv
effect
mannanco
liposom
dna
vaccin
evidenc
enhanc
stimul
cellular
immun
respons
similarli
opalmitoyl
mannanco
niosom
carrier
adjuv
system
hbv
dna
vaccin
deliv
oral
elicit
mucos
system
cellular
immun
respons
dextran
highli
hydrophil
neutral
polysaccharid
produc
certain
acid
lactic
bacteria
leuconostoc
mesenteroid
consist
main
chain
glucos
branch
larg
number
hydroxyl
group
make
good
target
modif
solubl
pattern
microbi
polysaccharid
sulfat
deriv
immunogen
proinflammatori
effect
mice
diethylaminoethyl
deae
dextran
polycation
deriv
contain
deae
group
link
glucos
evalu
veterinari
adjuv
inactiv
viru
vaccin
sinc
although
mechan
action
clear
effect
humor
respons
recogn
suggest
deaedextran
stimul
polar
respons
antibodi
synthesi
detect
administ
formalininactiv
venezuelan
equin
encephalomyel
viru
dextran
nanospher
entrap
ag
deae
also
use
adjuv
whole
cell
cholera
ag
deaedextran
shown
enhanc
immun
respons
deaedextran
adjuv
combin
wholecel
typhoid
vaccin
effect
activ
mous
protect
test
ttadjuv
vaccin
ag
alon
acetyl
dextran
acdex
dextran
deriv
synthes
revers
modif
dextran
hydroxyl
group
acet
motif
modifi
properti
acdex
base
particl
shown
alter
ag
present
mhc
ii
present
assay
acdex
waterinsolubl
biopolym
rel
stabl
ph
degrad
rapidli
acid
condit
lysosom
compart
ph
apc
properti
acdex
use
deliveri
agonist
imiquimod
intracellular
receptor
encapsul
imiquimod
acdex
microparticl
increas
immun
stimul
acdex
similarli
use
deliv
poli
c
cpg
adjuv
macrophag
phagosom
anoth
studi
use
acdex
microcarri
encapsul
recombin
protect
ag
agonist
resiquimod
anthrax
vaccin
develop
deaedextran
haemonchu
contortu
larvaspecif
ag
sheep
confer
greater
protect
alum
quil
aadjuv
vaccin
microspher
compos
blend
plga
dextran
also
develop
intramuscular
deliveri
hbsag
dextranbas
nanovaccin
induc
robust
immun
respons
incorpor
ova
lipopolysaccharid
dextran
np
stimul
apc
mannos
receptordepend
manner
well
strong
cellular
ova
peptidespecif
cell
humor
immun
respons
mice
dextran
chitosanbas
polyelectrolyt
complex
use
deliv
capsid
protein
lentinan
glucohexosebas
fungal
known
antitumor
properti
lentinan
shown
stimul
prolifer
blood
mononuclear
cell
lymphocyt
monocyt
macrophag
increas
resist
malign
transform
demonstr
effect
adjuv
cell
dna
vaccin
induc
specif
cell
immun
respons
rel
low
level
human
due
larg
size
lentinan
evalu
potenti
maxim
immun
elicit
dna
vaccin
lentinan
shown
immunomodulatori
abil
respiratori
influenza
viru
infect
act
synergist
bacillu
ag
activ
alveolar
macrophag
furthermor
lentinan
show
immunotherapeut
effect
along
dc
vaccin
treatment
melanoma
presenc
lentinan
enhanc
effici
dc
activ
natur
killer
cell
popul
via
stimul
ifng
product
adjuv
potenc
synthet
branch
glucohexos
analog
lentinan
demonstr
conjunct
hbv
core
ag
hbcag
encod
dna
vaccin
mice
lentinan
enhanc
recruit
matur
apc
cell
activ
increas
size
cell
popul
final
balbc
mice
hbsag
vaccin
elicit
humor
cellular
immun
respons
promot
apc
matur
ag
present
activ
cell
lead
express
antihbv
antibodi
product
zymosan
insolubl
prepar
saccharomyc
cerevisia
cell
wall
stimul
immun
cell
apc
phagocyt
receptor
express
dc
macrophag
induc
inflammatori
cytokin
product
via
nfkb
activ
also
stimul
differ
complement
pathway
balbc
mice
dna
vaccin
combin
zymosan
enhanc
humor
cellular
immun
respons
via
altern
pathway
promot
recruit
activ
apc
zymosan
activ
inflammasom
macrophag
dc
cryopyrin
inflammasom
apoptosisassoci
specklik
protein
contain
caspas
recruit
domain
addit
zymosan
act
synergist
mucos
adjuv
poli
c
influenza
vaccin
zymosan
may
enhanc
adjuv
activ
poli
c
increas
product
cytokin
ie
dc
result
simultan
activ
poli
c
induc
zymosaninduc
signal
pathway
interestingli
latter
could
provid
basi
develop
neonat
vaccin
adjuv
sinc
immatur
tlrmediat
innat
immun
neonat
depend
monocyt
rather
dc
cellulos
polysaccharid
compos
link
dglucos
unit
compon
cell
wall
plant
microcrystallin
cellulos
cellulos
deriv
carboxymethyl
cellulos
cmc
hydroxyethyl
cellulos
hec
hydroxypropyl
cellulos
hpc
hydroxypropylmethyl
cellulos
hpmc
recogn
popular
polymer
materi
routin
use
medic
pharmaceut
applic
especi
novel
cmcqc
quatern
cellulos
nanoparticl
proven
promis
vehicl
control
deliveri
protein
drug
cmc
qc
come
cellulos
natur
materi
good
toler
bodi
moreov
format
cmcqc
nanoparticl
physic
crosslink
electrostat
interact
instead
chemic
bond
therefor
possibl
toxic
deactiv
caus
chemic
crosslink
reagent
avoid
attract
featur
make
cmcqc
nanoparticl
potenti
carrier
prophylact
therapeut
activ
agent
dna
vaccin
cellulos
acet
phthalat
cap
anion
polym
compos
phthalic
acid
acet
thiolat
polym
intens
use
mucoadhes
polym
polym
form
coval
bond
thiol
group
thiolat
polym
cystein
rich
subdomain
mucu
glycoprotein
disulfid
bond
protein
subunit
vaccin
fmd
encapsul
tcap
microparticl
mp
import
develop
vaccin
deliveri
carrier
prevent
diseas
infect
mucosa
cap
also
activ
cap
micron
form
formul
cream
broad
spectrum
microbicid
inactiv
sever
sexual
transmit
diseas
std
pathogen
includ
pga
gpga
watersolubl
nontox
poli
amino
acid
produc
certain
strain
bacillu
gpga
compos
dand
lglutam
acid
unit
link
via
side
group
chemic
modifi
variou
bioactiv
ligand
modul
overal
polym
behavior
biodegrad
pga
biopolym
np
prepar
selfassembl
amphiphil
biopolym
hydrophil
gpga
hydrophob
lphenylalanin
ethyl
ester
shown
induc
agspecif
cellular
humor
immun
respons
follow
immun
variou
ag
ag
includ
ova
combin
gpganp
system
activ
immun
allergenspecif
immunotherapi
gpganp
use
activ
human
monocytederiv
dc
divert
immun
effici
cell
prime
addit
nextgener
nanovaccin
contain
japanes
enceph
viru
jev
likeparticl
encapsul
gpganp
provid
protect
jev
infect
mice
also
shown
gpganp
induc
immun
respons
myeloid
differenti
primari
respons
gene
signal
pathway
interestingli
gpganp
cpgodn
adjuv
found
act
synergist
via
macrophag
potent
induc
agspecif
cellular
immun
gpganp
investig
anticanc
effect
instanc
ovagpganp
suppress
growth
tumor
intranas
immun
ovaload
gpganp
stimul
product
ctl
ifngsecret
cell
spleen
lymph
node
addit
ovagpga
nanovaccin
confer
resist
tumor
challeng
cell
inhibit
lung
metastasi
cell
effect
confirm
separ
studi
infectionmimick
ovagpganp
enhanc
function
dc
ag
uptak
migrat
lymph
node
crosspresent
vaccin
ovagpganp
protect
mice
tumor
challeng
suppress
tumor
growth
gener
longlast
immun
respons
fig
interestingli
tailor
immun
respons
induc
gpgananovaccin
instanc
finetun
hydrophob
amino
acid
ethyl
ester
aae
gpgaaaeova
nanocomplex
final
gpgagraftlphenylalanin
ethyl
esterbas
polyion
complex
potenti
ag
carrier
adjuv
thu
gpganp
excel
adjuv
potenti
act
stimul
arm
immun
respons
biodegrad
materi
serv
basi
develop
subunit
agbas
prophylact
nucleic
acidbas
therapeut
vaccin
owe
biocompat
minim
toxic
ensur
safeti
therapeut
efficaci
review
discuss
repres
biodegrad
polym
immun
respons
elicit
case
biomaterialbas
particul
vaccin
deliv
ag
act
adjuv
shown
enhanc
immun
respons
compar
formul
compris
ag
alon
particular
mucoadhes
polym
polym
intrins
abil
increas
crosspresent
ag
induc
ctlmediat
immun
respons
signific
improv
classic
alumadjuv
vaccin
biomateri
acceler
clinic
translat
new
vaccin
ebola
tb
hiv
infect
cancer
howev
greater
understand
physiochem
properti
eg
size
shape
charg
biomateri
mechan
stimul
immun
need
develop
effect
vaccin
addit
recent
advanc
materi
engin
appli
custom
vaccin
meet
specif
immunolog
need
instanc
recent
develop
artifici
agpres
cell
cell
membranemedi
biofunction
approach
use
tool
rapidli
grow
field
immunotherapi
author
help
research
write
proofread
review
articl
author
declar
conflict
interest
